Canopy
Zellkraftwerk

TruSight® Myeloid Sequencing Panel For RareSeq™

The TruSight® Myeloid panel uses NGS technology to provide a comprehensive assessment of 54 genes in a single assay. RareSeq™ error corrected sequencing brings further clarity enabling the identification of ultra rare somatic mutations in hematologic malignancies. This Myeloid panel targets genes known in peer-reviewed literature to be frequently mutated in leukemia and myeloproliferative disorders.

Myeloid sequencing panel

Benefits

01

Comprehensive assessment of 54 genes in one assay

02

Cost effective and efficient workflow to study multiple variants of myeloid malignancies

03

100% coverage of all targeted regions

Genes in panel


Download full list
(12 KB)

Details & Data

Current methods to study multiple variants of myeloid malignancies are time-consuming, expensive and may not determine the underlying genetic cause of the disease. Additionally, low copy number variants for early detection can be missed in patient samples. RareSeq™ solves this problem by error correcting the NGS results to identify true genetic variants that in the past would have been misclassified as an error.

RareSeq™ error corrected sequencing is a proprietary UMI strategy combined with a custom bioinformatics analysis which allows for ultrasensitive variant detection. The bioinformatics alignment of the UMIs allows for more accurate allele quantitation as well as increased sensitivity for variant detection. For more information on how RareSeq™ works to error correct sequencing data, click here.

The TruSight® Myeloid panel from Illumina targets 54 genes known to be frequently mutated in myeloid malignancies providing a comprehensive assessment of disease development and progression in leukemia and myeloproliferative disorders such as:

  • Acute myeloid leukemia (AML)
  • Myelodysplastic syndrome (MDS)
  • Myeloproliferative neoplasms (MPN)
  • Chronic myelogenous leukemia (CML)
  • Chronic myelomonocytic leukemia (CMML)
  • Juvenile myelomonocytic leukemia (JMML)

This panel is comprised of a highly optimized oligo pool specific for researching genomic changes associated with tumor suppressor genes and oncogenic hotspots in hematologic malignancies. Features include ~141 kb of genomic content, consisting of 568 amplicons of ~250 bp in length; an oligo pool targeting 15 full genes (exons only), plus exonic hotspots of an additional 39 genes, providing nearly 100% coverage of all targeted regions.

GeneTarget Region (exon)GeneTarget Region (exon)GeneTarget Region (exon)GeneTarget Region (exon)
ABL14-6DNMT3AfullKDM6AfullRAD21full
ASXL112ETV6/TELfullKIT2, 8-11, 13, 17RUNX1full
ATRX8-10, 17-31EZH2fullKRAS2, 3SETBP14 (partial)
BCORfullFBXW79-11MLL5-8SF3B113-16
BCORL1fullFLT314, 15, 20MPL10SMC1A2, 11, 16, 17
BRAF15GATA12MYD883-5SMC310, 13, 19, 23, 25, 28
CALR9GATA22-6NOTCH126-28, 34SRSF21
CBL8, 9GNAS8, 9NPM112STAG2full
CBLB9, 10HRAS2, 3NRAS2, 3TET23-11
CBLC9, 10IDH14PDGFRA12, 14, 18TP532-11
CDKN2AfullIDH14PHF6FullU2AF12, 3
CEBPAfullIKZF1fullPTEN5, 7WT17, 9
CSF3R14-17JAK212, 14PTPN113, 13ZRSR2full
CUX1fullJAK313

Request a quote

Pricing

TruSight® Myeloid Sequencing Panel For RareSeq™

TruSight® Myeloid Panel covers 54 genes found to be mutated in hematologic malignancies.

TruSight® is a registered trademark of Illumina, Inc. and is used without permission. No challenge to the rights of Illumina is intended or implied.

Tags: ,
0

Start typing and press Enter to search